Navigation Links
Resverlogix Completes Dosing for ASSERT Trial
Date:5/12/2010

pare the dose and time response relationship for ApoA-I as well as to examine key reverse cholesterol markers involved with HDL functionality.

In related clinical news the parallel Phase 2 ASSURE trial for RVX-208, which announced its first site activation on February 25th, will be reassessing its enrollment procedure. Since the ASSERT trial provides us with data much faster than first anticipated, we can also now apply pertinent findings to the ASSURE trial. In order to expedite enrollment, while continuing our primary patient safety concerns, the ASSURE trial is being voluntarily halted on a temporary basis in order to modify enrollment procedures. "While the ASSERT trial set records for enrollment, the much more intricate ASSURE trial will not for the reason that the inclusion criteria is much more detailed and intensive. ASSURE currently requires a patient must have had a heart attack within the past four weeks. The patient is then required to voluntarily submit to having two invasive Intravascular Ultrasound (IVUS) both at the start and finish of the 90 day drug treatment period. We believe that we can enhance the enrollment procedure by modifying the inclusion criteria. One such option would be to include any patients sent to the Catheter Lab, thus greatly increasing the pool of patients that we would be able to draw from for enrolment in this trial. Patients will also now benefit from any added knowledge that we are about to gain from the successful completion of dosing in the ASSERT trial," stated Donald McCaffrey.

In other news today, Donald J. McCaffrey will be providing an updated corporate and clinical overview at 1:00 pm EDT. A slide presentation will be followed by a question and answer session regarding the impact of the early completion of the ASSERT trial and the enh
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Globally, approximately 418 million,people are currently infected with ... hepatitis in the 21st century cannot be,understated or ... by Kalorama Information. Paradoxically, despite the obvious ... to contain hepatitis. Yet the incidence and,prevalence of ...
... Tuesday, September 11, 2007 - 11:00 a.m. ET; 8:00 ... 6 /PRNewswire-FirstCall/ - MIGENIX,Inc. (TSX: MGI; OTC: MGIFF), a ... conference call and webcast on Tuesday,September 11, 2007 at ... for the first fiscal quarter ended July 31, 2007. ...
... Inc.,(Nasdaq: VRUS ) and Roche (OTC: RHHBY) ... for the treatment of chronic hepatitis C,virus (HCV) ... on Hepatitis C,Virus and Related Viruses being held ... prodrug of PSI-6130, is an oral cytidine nucleoside,analog ...
Cached Biology Technology:Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health 2MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 5
(Date:4/17/2014)... Our eyes not ... with a continuous stream of information about our own movements. ... a car the world glides by us and leaves ... our brain calculates self-motion from this "optic flow". This way, ... during our own movements. Together with biologists from the University ...
(Date:4/17/2014)... Rajendra Singh Thursday as a "Champion of Change" ... deployment in the residential, commercial and industrial sectors. ... Electrical and Computer Engineering and director of Clemson,s ... hero leading the charge across the country to ... and driving policy changes at the local level ...
(Date:4/17/2014)... a novel method to help kidney stone sufferers ... treatment possible., Kidney stones represent a major medical ... left untreated, apart from being particularly painful, they ... In many patients treated successfully, stone recurrence is ... approach to diagnosis and treatment needs to be ...
Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... shedding light on possible causes of infertility and autoimmune ... and florescent genes to illuminate cells that produce a ... lupus. The technique will help scientists track the ... ensuring supplies of breast milk in nursing mothers but ...
... Belfast academic has shown that crabs not only suffer pain ... study, which looked at the reactions of hermit crabs to ... and Mirjam Appel from the School of Biological Sciences at ... Behaviour . Professor Elwood, who previously carried out a ...
... fish stocking has on aquatic insects in mountain lakes ... to a study completed by U.S. Forest Service and ... a current online issue of the journal Freshwater Biology ... fisheries management practices now in use in California mountain ...
Cached Biology News:Crabs' memory of pain confirmed by Queen's academic 2Study assesses impact of fish stocking on aquatic insects 2
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... PrecisION Ion Channel Cell Lines ,High ... ,Ion channels are well known for having ... function and consequently have a key function ... that modulate ion channels have been investigated ...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Biology Products: